BMBF

GlioTraceGenOmics

Developing of a minimally invasive approach to early detection and individualized molecular diagnostics of treatment-refractory glioblastoma using Illumina high throughput sequencing. Subproject: Identification of molecular markers from recGB using Whole Exome Sequencing (WES).

GlioTraceGenOmics

Development of a novel approach to personalized molecular diagnostics of treatment-refractory glioblastoma

 

This project is supported by the German Federal Ministry of Education and Research (BMBF) and administered by Deutsches Zentrum für Luft- und Raumfahrt DLR Projektträger under Work programme RUS_Inno2017-148, grant 01DJ19002

 

Summary of the project:

Glioblastoma multiforme (GBM) is one of the most aggressive types of cancer causing >120.000 human deaths annually. Globally, over 0.3 billion $ is spent annually for treatment of GBM. Recent developments in Next Generation Sequencing (NGS) technologies opened a new era in biomedicine by enabling fast and cost-effective high throughput analysis of exome regions linked with identification of mutations.

GlioTraceGenOmics aims at developing a minimally invasive approach to early detection and individualized molecular diagnostics of treatment-refractory glioblastoma (GB). GlioTraceGenOmics utilizes state-of-theart methodologies to address unmet needs in the clinical management of GB considering existing challenges and recent scientific advances in the understanding of GB biology. GlioTraceGenOmics will address knowledge gaps on genetic landscapes of recGBs and develop an innovative, molecularly guided approach to patient stratification and prediction of individualised treatment response in recGB. The key innovations of GlioTraceGenOmics include:

 

  • Focus on recGBs, which are only scarcely investigated today.
  • Exploration of potential benefits and limits of individualized cancer therapy (ICT) for recGB diagnostics.
  • Longitudinal approach to real-time monitoring of the disease under therapy.
  • Exploration of the possibility of early diagnostics of recGBs; 4) a new diagnostic service model integrating commercial biotechnology (SMEs) as a provider of state-of-the-art medical technology services.

 

Reseach objectives of GlioTraceGenOmics encompass the following:

 

  • Identify associations of particular gene mutation patterns with treatment-refractory recGBs considering the impact of intratumoural genetic heterogeneity
  • Evaluate the feasibility and diagnostic potential of circulating tumour DNA (ctDNA) screening for early diagnostics of recGBs.
  • Develop a computational model of GB recurrence.

Consortium members: Novel Software Systems LLC, Novosibirsk, Russia; International Neuroscience Institute Hannover GmbH, Hannover, Germany; ZipPrime Ltd. Ankara, Turkey; StarSEQ GmbH, Mainz, Germany

  OPEN CONTACT FORM